PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Advanced and Metastatic Breast Cancer Clinical Trial

Official title: Open, Multicenter, Phase Ic Clinical Study on the Pharmacokinetics and Drug Interactions of Utidelone Plus Capecitabine in Patients With Recurrent and Metastatic Breast Cancer

Status Completed

Clinical Trial Summary

This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.

The purpose of this trial is:

1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone.

2. To evaluate the drug interaction of utidelone and capecitabine.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced and Metastatic Breast Cancer
• Breast Neoplasms

• NCT number: NCT05052437
• Study type: Interventional
• Source: Beijing Biostar Pharmaceuticals Co., Ltd.
• Status: Completed
• Phase: Phase 1
• Start date: October 15, 2020
• Completion date: February 19, 2021